Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 92

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 92
---
 planned preclinical research and clinical trials. Liminatus could experience disruptions that could severely impact its business, current and planned preclinical research and clinical trials due to health epidemics or other outbreaks, including:

| ● | delays or difficulties in enrolling and retaining subjects in Liminatus’s ongoing preclinical research and Liminatus’s future clinical trials; |

| ● | delays or difficulties in clinical site initiation, including due to difficulties in staffing and recruiting at clinical sites; |

| ● | difficulties interpreting data from Liminatus’s clinical trials due to the possible effects of health epidemics, on subjects; |

| ● | diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as Liminatus’s clinical trial sites and hospital staff supporting the conduct of clinical trials; |

| ● | interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; |

| ● | limitations in resources, including Liminatus’s employees, that would otherwise be focused on the conduct of Liminatus’s business or its current or planned clinical trials or preclinical research, including because of sickness, the desire to avoid contact with large groups of people, or restrictions on movement or access to Liminatus’s facility as a result of government-imposed “shelter in place” or similar working restrictions; |

| ● | delays in receiving approval from regulatory authorities to initiate Liminatus’s clinical trials; |

| ● | interruptions in preclinical studies due to restricted or limited operations at the CROs conducting such studies; |

| ● | interruptions or delays in the operations of the FDA or other domestic or foreign regulatory authorities, which may impact review and approval timelines; |

| ● | delays in receiving the supplies, materials and services needed to conduct clinical trials and preclinical research; |

| ● | changes in regulations as part of a response to a health epidemic or outbreak which may require Liminatus to change the ways in which Liminatus’s clinical trials are conducted, which may result in unexpected costs or require Liminatus to discontinue the clinical trial altogether; |

| ● | interruptions or delays to Liminatus’s development pipeline; |

| ● | delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and |

| ● | refusal of the FDA to accept data from clinical trials in affected geographies outside of the